Metabolism
Clinical and Experimental
VOL 46, NO 8
A U G U S T 1997
Response to Nutritional and Growth Hormone Treatment in Progeria
J o s e E. A b d e n u r , W. Ted B r o w n , Silvia F r i e d m a n , M e l a n i e S m i t h , and Fima Lifshitz
Hutchinson-Gilford progeria syndrome (HGPS) is a rare condition with an unknown molecular defect. Patients with HGP
progressively develop failure to thrive (FTT), alopecia, loss of subcutaneous fat, scleroderma, stiffening of various joints, and
severe atherosclerosis. The median life span is 13 years, and the main cause of death is cardiovascular complications. There are
few reports of endocrine and metabolic studies because of the rarity of this condition, and the response to long-term growth
hormone (GH) treatment has not been described. We report the results of endocrine and metabolic studies performed to
investigate the etiology of growth failure in five patients with HGP. Additionally, the response to nutritional therapy (NT) and
GH treatment in three of these patients is presented. Our results suggest that elevated GH levels are characteristic of this
disease and that an elevated basal metabolic rate (BMR) could be the cause of the FTT seen in HGP. Nonaggressive NT slightly
improved weight gain and growth velocity (GV). Combined NT and GH treatment in three patients improved the GV, increased
the levels of growth factors, and paradoxically resulted in decreased BMRs. However, the response to these therapies
decreased over time and did not seem to prevent the progression of atherosclerotic disease.
Copyright© 1997by W.B. Saunders Company
UTCHINSON-GILFORD PROGERIA syndrome (HGPS)
is a rare condition with a reported incidence of 1 in 8
million births. ~,2 The diagnosis is based on clinical features,
which become typical by 2 to 4 years of age. They include
failure to thrive (FTT), alopecia, loss of subcutaneous fat,
scleroderma, stiffening of various joints, atherosclerosis, characteristic facies, and normal intelligence. 1-3 The median life span
is 13 years, and death is mostly due to cardiovascular complications. 4-6
H
There is no biochemical test to diagnose HGPS. These
patients may excrete increased amounts of hyaluronic acid, 7 but
the underlying molecular defect is unknown. The inheritance
pattern argues that it is due to an isolated sporadic dominant
mutation, although a few cases may be due to a germ line
mutation. 2,8 Endocrine and metabolic studies have been reported for individual patients. 9-15 However, it is uncertain
whether abnormal findings such as insulin resistance u or an
increased basal metabolic rate (BMR)15 occur in all individuals
with HGPS. We report the results of endocrine and metabolic
studies performed to investigate the etiology of growth failure
in five patients with HGR Additionally, the response to nutritional therapy (NT) and growth hormone (GH) treatment in
three of these patients is presented.
Our results suggest that elevated GH levels are characteristic
of this disease and that an elevated B M R could contribute to the
FTT seen in HGPS. NT resulted in a slight increase in weight
gain and growth velocity (GV). Combined NT and GH treatment improved growth, increased the levels of growth factors,
and paradoxically resulted in a decreased BMR. The response to
Metabolism, Vol 46, No 8 (August), 1997: pp 851-856
these therapies decreased over time and did not seem to prevent
the progression of atherosclerotic disease. Additionally, resistance to insulin and other hormones seems to develop in older
patients with HGPS.
SUBJECTS AND METHODS
Patients
Five patients with HGPS were studied over a 2-year period. The
diagnosis was confirmed by W.T. Brown, Director of the International
Progeria Registry. 2 In all cases, the family history was negative for birth
defects or consanguinity. The patients' clinical information at the time
of our initial evaluation is presented in Table 1. Patient no. 3 was the
subject of a previous report dealing with dental problems. 16The studies
were approved by the Hospital's Institutional Review Board. An
informed-consent form was signed by the parents and/or patients
according to their age.
From Miami Children's Hospital, Miami, FL; and The New York
State Institute for Basic Research in Developmental Disabilities, Staten
Island, NY.
Submitted July 27, 1995; accepted January 28, 199Z
Current address: J.E.A., Fundacion Para el Estudio de las Enfermedades Neurometabolicas, Buenos Aires, Argentina.
Supported in part t)3, a grant from the Bedminister Foundation and
the Maimonides Research and Development Foundation.
Address reprint requests to W. Ted Brown, MD, PhD, The New York
State Institute for Basic Research in Developmental Disabilities, 1050
Forest Hill Rd, Staten Island, NY 10314.
Copyright © 1997 by W.B. Saunders Company
0026-0495/97/4608-0001503.00/0
851
852
ABDENUR ET AL
Table 1. Clinical Characteristics of the Patients
Characteristic
Sex
Ethnicity
Birth weight (kg)/percentile
Birth length (cm)/percentile
Gestational age
Mother's age at birth (yr)
Father's age at birth (yr)
Age at diagnosis (yr)
Clinical presentation
Age (yr, initial evaluation)
History of diarrhea
Alopecia
Decreased subcutaneous
tissue
Xanthomas
Hip dislocation
Joint contractures
Pectus excavatum
Cardiac abnormalities
Headaches
Strokes/age at 1st episode
1
Patient No.
3
2
4
5
Male
White
3.24/50
50.5/75
Term
29
30
3.6
Female
White
2.75/25
49.5/50
Term
21
25
2.8
Male
Black
2.55/90
NA
33 wk
24
23
2
Female
White
3.02/25-50
53/90
Term
30
31
1.2
Male
White
2.75/50-75
50/75-90
36 wk
25
30
1
4.2
No
Partial
Mild
5.8
No
Total
Moderate
13.5
Yes
Total
Severe
8.3
No
Almost total
Moderate
6.9
Yes
Almost total
Mild
No
No
Severe
Mild
No
Yes
No
Severe
Mild
Mitral
Regurgitation
Yes
Yes/5.6 yr
No
Yes/bilateral
Mild
No
Angina
No
No
Mild
No
No
No
No
Mild
Mild
No
Yes
No
Yes
Yes/8.2 yr
Yes
No
No
No
Abbreviation: NA, not available.
*All patients had a high forehead, prominent veins, micrognathia, scleroderma, and FIT. Other findings, which varied from patient to patient,
a r e listed.
Initial Evaluation
]rests
All five patients underwent a physical examination, anthropornetry,
determination of BMR, biochemical nutritional evaluation, and endocrine testing (described later), which included measurement of spontaneous GH secretion, the GH response to GH-releasing hormone
(GHRH), and the endocrine response to a combined hormonal stimulation test.
For spontaneous GH secretion, blood was obtained through a heparin
lock every 20 minutes for 12 hours starting at 8:00 PM. The combined
hormonal stimulation test was performed at 9:00 AM as previously
described. 17For the GHRH stimulation test, after a 12-hour fast, 1 jag/kg
(1-44) hpGHRH-NH2 (Peninsula Laboratories, Belmont, CA) was
infused IV over 90 seconds. Blood for GH assay was obtained at 0, 15,
30, 45, 60, 90, and 120 minutes. The IVGTT was performed at 9:00 AM
after an overnight fast. Glucose was administered at 0.5 g/kg IV over 3
minutes. Blood for glucose and insulin assay was obtained at - 1 0 , 0, 1,
3, 5, 7, 10, 15, 20, 30, 45, 60, and 90 minutes. For the IGF-I generation
test, IGF-I and IGF binding protein-3 (IGFBP-3) were determined at
9:00 AM before and after 4 consecutive days of rhGH (0.06 mg/kg per
dose) administered at 7:00 PM.
NT
After the initial evaluation, patients no. 2, 3, and 5 were placed on NT
for periods of 4 to 10 months. NT was aimed to achieve the maximum
tolerated caloric intake without using tube feedings. The caloric
composition of the diet was maintained at 50% to 60% for carbohydrate,
25% to 30% for fat, and 15% to 20% for protein. Different high-calorie
supplements were used according to tolerance. Nutrient intake was
assessed through 24-hour dietary recalls obtained by a nutritionist on
semistructured interviews using food models and measuring devices as
a guide. The diet was analyzed with a nutrient analysis system
(NutriQuest II; Capital Systems, Kensington, MD).
Nutritional and GH Therapy
Patient no. 1 was readmitted a few weeks after the initial evaluation.
Patients no. 2, 3, and 5 were readmitted after NT. All of them underwent
an intravenous (IV) glucose tolerance test (IVGTT) followed by an
insulin-like growth factor-I (IGF-I) generation test. After that, patients
no. 1, 2, 3, and 5 were discharged on NT and GH treatment with
recombinant human GH at a dose of 0.06 mg/kg three times per week
(0.18 mg/kg/wk), Patients no. 1, 2, and 5 were evaluated for 6 to 18
months and readmitted every 3 to 6 months. Patient no. 3 could not be
reevaluated, and GH treatment was discontinued after 4 months. Patient
no. 4 underwent only the initial evaluation.
Other Evaluations
Height was measured with a Harpenden stadiometer (Holtain Limited, Crymych, UK). GV was assessed using the standards of Tanner and
DaviesY 8 Weight Z-score (WZS), height Z-score (HZS), weight for
height adequacy (W/H), and W/H Z-score (W/HZS) were calculated
using a computer program. 19 Pubertal status was evaluated by the
method of Tanner, 2° and bone age according to the TW2 method using
carpal bones. 21 All GH samples were assayed by a polyclonal radioimmunoassay (RIA) kit (Kallestad Diagnostics, Chaska, MN) with a
minimum detectable value of 1.5 jag/L (values < 1.5 lag/L were
considered as 1.5). Characteristics of the spontaneous GH secretion
were evaluated as previously described? 2 Normal values for all
endocrine tests were obtained from children with familial short stature
studied by our group with the same methodology. 23 IGF-I level was
measured with a kit from the Nichols Institute. IGF-II and IGFPB-3
levels were measured by RIA at Endocrine Sciences (Calabasas Hills,
CA). Pr0collagen III was assessed by RIA kits (Behring, Marburg,
Germany). Insulin level was measured with kits from Binax (South
NUTRITIONAL AND GH TREATMENT IN PROGERIA
853
Portland, ME). Insulin response during the IVGTT was evaluated by the
sum of the values at 1 and 3 minutes and compared with published
percentiles. 24 The glucose utilization rate (Kt) was calculated as
previously described] 7 BMR measurements were conducted after an
overnight fast, with the patient supine and awake and resting in a dark,
quiet room. A face mask was used in all children. The child was allowed
to become comfortable with the system until a stable baseline could be
obtained. At that point, test recordings were started. Oxygen consumption and C O 2 production rates were obtained from two 15-minute
gas-exchange recordings. Discomfort or physical activity led to discontinuation of the test. Oxygen consumption, carbon dioxide production,
and the respiratory quotient were measured with an open-circuit indirect
calorimeter (Sensormedics, Anaheim, CA). Standard computer programs were used to calculate energy expenditure (expressed as calories
per kilogram body weight per day) using the equations of Conzolazio et
a125 and Weir.26 BMR was predicted using Food and Agriculture
Organization of the United Nations/World Health Organization. equations (Geneva, Switzerland, 1985), and the results were expressed as
percentage measured/predicted. BMR studies performed with the same
methodology in 21 age-matched children with familial short stature
(mean age, 10.3 +_ 0.9 years; range, 3 to 14) were normal
(100.4% _+ 0.04%). 27 Total urinary nitrogen, used to calculate the
nonprotein respiratory quotient (NPRQ), was analyzed with the microNessler technique. Protein oxidation was estimated from total nitrogen,
and carbohydrate and fat utilization were calculated by the NPRQ. 28
Erythrocyte Na+K+ATPase activity was measured as previously described. 29 Measurements of the right midarm circumference and triceps
skinfold were performed using a Lange caliper (Cambridge Scientific
Industries, Cambridge, MD). Arm muscle and fat areas were calculated
as previously described. 3°
normal for age and sex. The B M R was markedly elevated,
ranging from 182% to 215% of normal for age and sex (Fig 1).
BMRs were also elevated when compared with normals for
weight or height (data not shown). Evaluation of the NPRQ
showed that patients no. 3 and 4 had high fat use and patient no.
2 a high protein use. Levels of triiodothyronin (T3), reverse T3,
thyroxine (T4), free T4, and thyrotropin (TSH) were normal and
the TSH response to TSH-releasing hormone was borderline
high in all patients. Erythrocyte Na+K+ATPase activity, measured in patients no. 1, 2, and 3, was normal. Retinol-binding
protein and prealbumin levels overall were low, whereas
albumin, magnesium, zinc, vitamin E, cholesterol, triglycerides,
free fatty acids, [3-OH-butyrate, and amino acids were normal
(data not shown).
The five patients demonstrated severe growth retardation
(Table 2), with a HZS of - 4 . 9 2 to - 6 . 5 0 and abnormal GV.
However, high GH levels were obtained in the spontaneous
and/or stimulated GH secretion tests. Levels of IGF-II and
IGFBP-3 were low or borderline low in patients no. 1 and 2.
Bone age was normal in all but patient no. 1, whose bone age at
4.2 years was 2.7 years. Cortisol, prolactin, luteinizing hormone
(LH), and follicle-stimulating hormone levels were measured in
the combined hormonal stimulation test and were normal,
except for patient no. 3 with high LH and prolactin responses
(120 MIU/mL and 63.5 Mg/L, respectively). His total testosterone level was 173 ng/dL.
Response to Nutritional Treatment
RESULTS
Initial Evaluation
Results of the initial evaluation are summarized in Table 2.
All patients showed anthropometric indices suggestive of
malnutrition: decreased WZS, W/H adequacy, W/HZS, and
overall low skinfold thickness. However, caloric intake was
Patients no. 2, 3, and 5 underwent NT. During treatment, their
caloric intake increased 23% to 38% above basal. However,
weight gain was poor and growth rate improved only slightly,
remaining at less than the normal limits for age. There were no
significant changes in the levels of growth factors. B M R
remained markedly elevated. Retinol-binding protein and preal-
Table 2. Results of the Initial Evaluation
Patient No.
Parameter
Age (yr)
WZS
W/H adequacy
W/HZS
Arm muscle area (mm 2)
Arm fat area (mm 2)
Caloric intake (cal/kg/d)
BMR (% of normal)
Substrate use, CHO/protein/fat (% of total
calories)
HZS
GV (cm/yr)
Mean spontaneous GH secretion (pg/L)
Peak [GH] combined hormonal stimulation
(pg/L)
Peak [GH] GHRH (pg/L)
IGF-I
IGF-II
IGFBP-3
*Below normal for age/sex.
t A b o v e normal for age/sex.
1
2
3
4
5
4.2
-4.05
78.8
-2.34
1,036"
318"
108
195
5.8
-5,45
64.4
-3.83
770*
163"
99
182
13.5
-4.36
73.8
NA
1,755"
170"
87
214
8.3
-4.11
71.6
-3.23
1,015"
187"
83
215
6.9
-4.42
78
-2.52
1,152"
328*
144
NA
47/10/43
4.92
2*
8.3~
52/18/30
-6.5
2.8*
6.9t
17/10/73
- 5.37
3.3*
111-
26/10/64
-4.93
3.8*
8.9t
NA
-5.28
3.3*
4.3
8.4
24.1t
59
317"
1.6
26.6t
3,9
545
381
3.8
14.2
9.7
230
504
3
20.1t
82.8t
118
433
2.3
38.61
92.2t
50
312"
1.2"
854
ABDENUR ET AL
bumin increased to normal limits, and serum levels of albumin,
Mg, Zn, vitamin E, and amino acids did not change significantly.
within normal limits. However, results of the IVGTT showed a
borderline low insulin response and glucose Kt.
Long-Term Follow-up
Response to the IGF-I Generation Test
Response was positive in the four patients studied (no. 1, 2, 3,
and 5), with increase in IGF-I and IGFBP-3 levels from 242% to
600% and 122% to 200%, respectively.
Response to NT and GH Therapy
Patients no. 1, 2, and 5 underwent this combined treatment
for 18, 6, and 12 months, respectively. Patient no. 1 was able to
maintain a caloric intake of 17% above the baseline during the
first 6 months, when he had a stroke. After that, his caloric
intake could not be sustained and decreased to a mean of 90
cal/kg/d. Patients no. 2 and 5 were able to maintain a mean
caloric intake of 24% and 20% above the baseline, respectively,
throughout GH treatment. Weight gain in the three patients was
poor. GV increased to 5.0, 7.0, and 4.5 cm/yr, respectively.
However, the effect on GV was more pronounced in the first 4
months. Levels of IGF-I, IGF-II, and IGFBP-3 increased, and
there was also an increase in procollagen and hydroxyproline
levels compared with pretreatment values (data not shown).
Patients no. 1 and 2 showed a marked decrease in BMR, which
was sustained throughout the treatment (Fig 1). Both patients
also showed an increase in the use of protein, reaching 15.7%
and 25.9%, respectively. T3 levels increased in the three
patients, whereas T4, free T4, and erythrocyte Na+K+ATPase
activity remained within normal levels.
Carbohydrate Metabolism
Results are summarized in Table 3. Before GH treatment,
patients had normal serum levels of hemoglobin Alc (HbAlc)
and glucose. Islet cell antibodies and insulin autoantibodies
were not detected. Insulin levels were normal in all but patient
no. 3, who had extremely high levels during both fasting and the
IVGTT. During GH therapy, patients no. 2 and 5 maintained
normal glucose and HbA~c with increased insulin levels. In
patient no. 1, HbA~c increased to slightly above the upper
normal limits while fasting glucose and insulin levels remained
220
210200190
A
180
17o
160.
¢
150
140
130
120
110
100
BASAL
Fig 1.
NT
BMR response to treatment.
NT+GH
Patient no. 1 died at the age of 7.5 years of a new stroke.
Patients no. 2, 3, and 4 died of myocardial infarction at ages 6.9,
14.5, and 9.3 years, respectively. Autopsy was not performed in
any of the patients. Patient no. 5 is in good clinical condition
without signs of cardiovascular disease at age I1 years.
DISCUSSION
This study reports the clinical, nutritional, and endocrine
characteristics of five patients with HGPS and the response in
three of them to NT and GH therapy.
All of the patients had markedly decreased WZS, W/H
adequacy, W/HZS, and skinfold thickness, a pattern resembling
that of severe malnutrition. However, none of them had clinical
or biochemical features suggestive of chronic protein deficiency
(kwashiorkor) 31 or the intellectual deficits expected in a child
with chronic calorie deprivation (marasmus). 32-34 Moreover,
while receiving NT, our patients showed only a modest increase
in weight gain, GV, and growth factors. Previous studies failed
to demonstrate malabsorption in HGPSIS; therefore, it is
possible that their FTT is associated with an increased energy
expenditure due to an elevated BMR. This possibility is
sustained by our findings and those of a previous report. 15 The
cause of the elevated BMR is not clear. Thyroid function,
Na+K+ATPase activity, and protein turnover, which are known
to affect the BMR, were normal in our patients. It is therefore
possible that the high BMR seen in HGPS reflects alterations in
mitochondrial oxidative phosphorylation and/or respiration.9
It is known that substrate use varies with the nutritional status
of the patient, changing from normal to high fat use and
subsequently to high protein use as a source of energy.35
Accordingly, patient no. 1, whose W/H adequacy was close to
normal, had a normal substrate use, patients no. 3 and 4 (W/H
adequacy, 73.8% and 71.6%) showed an increased fat use, and
patient no. 2 (W/I-I adequacy, 64.4%) had a high protein use.
All patients showed severe growth failure with increased GH
levels. Additionally, growth factor levels in patients no. 1 and 2
were marginally low. This pattern, suggestive of a relative GH
resistance, has been described in protein-calorie malnutrition, 36,37 and it is considered a secondary GH insensitivity
syndrome. 38 It is also possible that the patients' low body fat
could have contributed to the high GH secretion. 39
Previous studies in HGP demonstrated no receptor or postreceptor defect to IGF activity. 13 On this basis, a treatment that
would increase growth factor levels should improve growth in
these patients. The results of the IGF-I generation test showed a
good response, and accordingly, the three patients who underwent GH treatment showed an increase in growth rate above the
levels attained with NT alone. The response correlated with an
increase in growth factors, procollagen III, and hydroxyproline,
demonstrating an anabolic effect of GH. However, the response
to GH decreased over time, probably due to the limited success
in improving the patient's nutrition. However, considering the
relative GH insensitivity of these patients, it is possible that a
higher GH dose could have improved these results.
855
NUTRITIONAL AND GH TREATMENT IN PROGERIA
Table 3. Carbohydrate Metabolism Response to NT and GH Therapy
Patient No.
1
Basal
HbAlc (5%-8%)*
Basal glucose (mg/dL)
Basal insulin (#U/mL)
Peak insulin (1 + 3 min)
Percentile
Glucose Kt (>1.2)*
5.9
86
4 mo
9.4
8 mo
8.2
2
12 mo
18 mo
9.3
Basal
8
7.1
3
4 mo
7.3
6 mo
7.3
6.3
NA
NA
80
64
NA
1,996
NA
~50
95
78
77
78
86
78
13
141
NA
99
10
91
8
56
8
68
15
118
22
254
10-50
10-50
10-50
1-5
5
10-50
>50
1.6
1.5
2
1.2
1.7
2
NA
2.1
5
Basal
1.8
Basal
3 mo
6 mo
NA
NA
NA
NA
4
NA
20
NA
12
54
97
1-5
10-50
4.4
3.6
115
10-50
4
NOTE. Peak insulin is the sum of insulin levels at 1 and 3 minutes during the IVGTT.
*Normal values.
It is known that GH treatment increases the B M R via an
increase in lean body mass. 4° In contrast, these HGPS patients
had a decrease in B M R during GH treatment, suggesting a more
efficient energy utilization.
Four of our five patients died of cardiovascular complications. One of them was never placed on NT or GH treatment,
and two had cardiovascular problems that preceded treatment.
Therefore, it is unlikely that the treatment affected mortality in
these patients.
Patient no. 3, the oldest of our HGP patients, showed severe
hyperinsulinism resembling the level s reported by Rosenbloom
et a111 in a 15-year-old patient with HGPS who developed
hyperglycemia. Further investigations in that patient suggested
a postreceptor defect in insulin action. 14 According to our
results and those of Rosenbloom et al; it appears that severe
insulin resistance may develop in adolescence in HGPS patients, first with normal glucose tolerance and later with
hyperglycemia. Additionally, patient no. 3 had exaggerated LH
and prolactin responses, which suggests that a generalized
hormone resistance develops in HGP patients, probably related
to an accelerated process of aging.4 l
As expected in children under GH treatment, 42 patients no. 2
and 5 maintained normal glucose tolerance and developed mild
hyperinsulinism. Conversely, patient no. 1 showed a decrease in
the first peak insulin response during the IVGTT. This response
has been considered an early predictor of insulin-dependent
diabetes mellitus. 24 Although this possibility cannot be ruled
out, these abnormalities seemed to be unique to this patient.
We conclude that an elevated B M R is likely to play a role in
the FTT in HGPS and that elevated GH levels are characteristic
of the disease. Nonaggressive NT slightly improved weight gain
and GV. GH treatment further increased the levels of growth
factors and paradoxically decreased the BMR. GV improved,
but this effect decreased over time. Furthermore, resistance to
insulin and probably to other hormones seemed to develop in
older patients. The cause of the elevated B M R and hormonal
abnormalities, resulting from a presumed dominant genetic
mutation in HGPS, has yet to be determined.
ACKNOWLEDGMENT
Part of this study was performed while the authors were affiliated
with the Department of Pediatrics of North Shore University Hospital,
Manhasset, N Y. We thank Drs Pierini, Lejarraga, Rivarola, and Ciaccio
(Hospital de Pediatria J.R Garrahan, Buenos Aires, Argentina) for their
cooperation in the study of patient no. 5, and M. O'Connor, M.
Zdan0wicz, and H. Spencer for technical assistance.
REFERENCES
1. DeBusk FL: The Hutchinson-Gilford progeria syndrome. J Pediatr
80:697-724, 1972
2. Brown WT, Zebrower M, Kieras FJ: Progeria: A genetic disease
model of premature aging, in Harrison DE (ed): Genetic Effects on
Aging, vol 2. Caldwell, NJ, Telford, 1991, pp 521-542
3. Brown WT, Kieras FJ, Houck GE, et al: A comparison of adult and
childhood progerias: Werner syndrome and Hutchinson-Gilford progeria syndrome. Adv Exp Med Biol 190:229-244, 1985
4. Baker PB, Babe N, Boesel CP: Cardiovascular abnormalities in
progeria. Arch Pathol Lab Med 105:384-386, 1981
5. Smith WS, Wiznitzer M, Karaman BA, et al: MRA detection of
vascular occlusion in a child with progeria. AJNR Am J Neuroradiol
14:441-443, 1993
6. McCandless BK, Cooper JA: Myocardial perfusion imaging with
pharmacologic stress in a 9-year-old girl. Clin Nucl Med 19:344-345,
1994
7. Kieras FJ, Brown WT, Houck GE, etal: Elevation of urinary
hyaluronic acid in Werner syndrome and progeria. Biochem Med Metab
Biol 36:276-282, 1985
8. Jones K, Smith P, Harvey M, etal: Older paternal age and fresh
gone mutation: Data on additional disorders. J Pediatr 86:84-88, 1975
9. Villee DB, Nichols G, Talbot NB: Metabolic studies in two boys
with classical progeria. Pediatrics 43:207-216, 1969
10. Rosenbloom AL, Karacan IJ, DeBusk FL: Sleep characteristics
and endocrine response in progeria. J Pediatr 77:692=695, 1970
11. Rosenbloom AL, Kappy MS, DeBusk FL, et al: Progeria: Insulin
resistance and hyperglycemia. J Pediatr 102:400-402, 1983
12. Harley CB, Goldstein S, Posner BI, et al: Decreased sensitivity
of old and progeric human fibroblasts to a preparation of factors with
insulin like activity. J Clin Invest 68:988-994, 198i
13. Conover CA, Dollar LA, Rosenfeld RG, et al: Somatomedin
C-binding and action in fibroblasts from aged and progeric subjects. J
Clin Endocrinol Metab 60:685-691, 1985
14. Rosenbloom AL, Goldstein S, Yip CC: Insulin binding to
cultured human fibroblasts increases with normal and precocious aging.
Science 193:412-415, 1976
15. Talbot NB, Butler AM, Pratt EL, et el: Progeria: Clinical
metabolic and pathologic studies on a patient. Am J Dis Child
69:267-279, 1945
16. Hasty Mr, Vann WF: Progeria in a pediatric dental patient:
Literature review and case report. Pediatr Dent 10:314-319, 1988
17. Ginsberg LJ: A practical approach to tolerance testing in
856
children, in Lifshitz F (ed): Pediatric Endocrinology (ed 2). New York.
NY, Dekker. 1990, pp 953-982
18. Tanner JM, Davies PSW: Clinical longitudinal standards for
height and height velocity for North American children. J Pediatr
107:312-329. 1985
19. Jordan MD: Centers for Disease Control Anthropometric Softward Package (CASP), version 3.0. Atlanta. GA. Centers for Disease
Control,. 1987
20. Tanner JM: Growth at Adolescence fed 2). Oxford. UK, Blackwell Scientific, 1962
21. Tanner JM. Whitehouse RH. Marshall WA. et al: Assessment of
skeletal maturity and prediction of adult height. London. UK. Academic. 1975
22. Veldhuis JD. Johnson ML: A novel general biophysical model
for simulating episodic endocrine gland signaling. Am J Physiol
255:E740-E759. 1988
23. Abdenur JE, Pugliese MT, Cervantes C. et al: Alterations in
spontaneous growth hormone secretion and the response to growth
hormone releasing hormone in children with non organic nutritional
dwarfing. J Clin Endocrinol Metab 75:930-934. 1992
24. Srikanta S. Ganda OP, Gleason RE. et al: Pre-type I diabetes:
Linear loss of beta cell response to intravenous glucose. Diabetes
33:717-720. 1984
25. Conzolazio CF, Johnson RE, Pecora LJ: Physiological Measurements of Metabolic Functions in Man. New York. NY. McGraw-Hill,
1963
26. Weir JB: New methods for calculating metabolic rate with
special reference to protein metabolism. J Physiol 109:1-9, 1949
27. Friedman S, Smith M, Shih-Yu Lee R et al: Energy metabolism
and fuel utilization in nutritional dwarfing children. J Am Coll Nutr
10:A61. 1991 (abstr)
28. Bumstein S. Glaser P, Trichet B. et al: Utilization of protein,
carbohydrates and fat in fasting and post absorptive subjects. Am J Clin
Nutr 33:998-1001. 1980
29. Lifshitz F, Friedman S, Smith MM; et al: Nutritional dwarfing: A
growth abnormality associated with reduced erythrocyte Na--K+ATPase
activity. Am J Clin Nutr 54:997-1004, 1991
ABDENUR ET AL
30. Frisancho AR: New norms Of upper limb fat and muscle areas for
assessment of nutritional status. Am J Clin Nutr 34:2540-2545, 1981
31. Rossouw JE: Kwashiorkor in North America. Am J Clin Nutr
49:588-592, 1989
32. MacLean WC Jr: Protein energy malnutrition, in Grand R,
Sutphen JL, Dietz WH (eds): Pediatric Nutrition: Theory and Practice.
Boston, MA, Butterworth, 1987, pp 421-431
33. Winick M, Rosso P: Head circumference and cellular growth of
the brain in normal and marasmic children. J Pediatr 74:774-778 , 1969
34.. Galler JR, Ramsey FC, Morley DS, et al: The long-term effects
of early kwashiorkor compared with marasmus. IV. Performance On the
National High School Entrance Examination. Pediatr Res 28:235-239,
1990
35. Kerr DS, Stevens MCG, Robinson HM: Fasting metabolism in
infants. Effect of severe undernutritiorl on energy and protein utilization. Metabolism 27:411-435, 1978
36. Parra A, Garza C, Garza Y; et al: Changes in growth hormone,
insulin and thyroxine values mad in energy metabolism Of marasmatic
children. J Pediatr 83:133-142, 1973
37. Underwood LE, Clemmons DR, Maes M, et al: Regulation of
somatomedin~C by nutrients. Horm Res 24:166-176, 1986
38. Laron Z, Blum W, Chatelain P, et al: Classification of growth
hormone insensitivity syndrome. J Pediatr 122:241, 1993
39. Abdenur J, Vaquero Solans C, Smith M, et al: Body composition
and spontaneous growth hormone secretion in normal children with
short stature. J Clin Endocrinol Metab 78:277-282, 1994
40. Walker JM, Bond SA, Voss LD, et al: Treatment of short normal
children with growth hormone: A cautionary tale? Lancet 336:13311334, 1990
41. Blackman MR: Aging and endocrinology, in Becker KL (ed):
Principles and Practice of Endocrinology and Metabolism, Philadelph!a, PA! Lippincott, 1990, pp 1461 - 1471
42. Walker J, Chanssain JL, Bougneres PF: Growth hormone
treatment of children with short Stature increases insulin secretion but
does not impair glucose disposal. J Clin Endocrinol Metab 69:253-258,
1989